argenex SE $ARGX Stake Raised by Fiera Capital Corp

Fiera Capital Corp increased its holdings in argenex SE (NASDAQ:ARGX) by 27.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,971 shares of the company’s stock after acquiring an additional 48,317 shares during the period. Fiera Capital Corp owned about 0.37% of argenex worth $190,030,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Capital World Investors lifted its stake in argenex by 0.4% in the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares in the last quarter. M&T Bank Corp lifted its stake in argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after acquiring an additional 774,916 shares in the last quarter. Wellington Management Group LLP lifted its stake in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Bank of America Corp DE lifted its stake in argenex by 1.9% in the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after acquiring an additional 6,259 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Stock Performance

Shares of ARGX stock opened at $891.32 on Monday. The stock’s 50 day simple moving average is $794.90 and its 200 day simple moving average is $812.60. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market capitalization of $55.43 billion, a price-to-earnings ratio of 39.68, a PEG ratio of 1.36 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The business had revenue of $1.31 billion for the quarter. On average, analysts forecast that argenex SE will post 26.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on ARGX. Guggenheim increased their price objective on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wedbush reissued an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research note on Thursday. HC Wainwright upped their target price on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Royal Bank Of Canada dropped their target price on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Finally, Robert W. Baird upped their target price on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.